Xenetic Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XBIO research report →
About the company
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients.
- CEO
- James F. Parslow
- IPO
- 2016
- Employees
- 2
- HQ
- Framingham, MA, US
Price Chart
- Market Cap
- $5.23M
- P/E
- -2.25
- P/S
- 1.64
- P/B
- 0.91
- EV/EBITDA
- 0.95
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -75.05%
- Net Margin
- -70.03%
- ROE
- -39.28%
- ROIC
- -34.45%
- Revenue
- $2.98M · 19.04%
- Net Income
- $-2,680,860 · 32.31%
- EPS
- $-1.58 · 38.52%
- Op Income
- $-2,834,582
- FCF YoY
- 18.84%
- 52W High
- $13.93
- 52W Low
- $1.90
- 50D MA
- $3.05
- 200D MA
- $2.93
- Beta
- 2.20
- Avg Volume
- 16.51K
Get TickerSpark's AI analysis on XBIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 21, 26 | PARSLOW JAMES F | other | 100,000 |
| Dec 31, 25 | VINOGRADOV ALEXEY ANDREEVICH | other | 2,500 |
| Dec 31, 25 | Dastoor Firdaus J. | other | 2,500 |
| Dec 31, 25 | Kornberg Roger D. | other | 2,500 |
| Dec 31, 25 | Borisenko Grigory G. | other | 2,500 |
| Dec 11, 24 | Kornberg Roger D. | other | 2,500 |
| Dec 11, 24 | Borisenko Grigory G. | other | 2,500 |
| Dec 11, 24 | Dastoor Firdaus J. | other | 2,500 |
| Dec 11, 24 | VINOGRADOV ALEXEY ANDREEVICH | other | 2,500 |
| Jun 18, 24 | PARSLOW JAMES F | other | 20,000 |
Our XBIO coverage
Recent articles, reports, and earnings notes.
No research on XBIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XBIO report →Similar companies
Peers in the same neighborhood.